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Type 1 diabetes (T1D) remains a major health problem worldwide,
with a steadily rising incidence yet no cure. Phosphoinositide
3-kinase-g (PI3Kg), a member of a family of lipid kinases expressed
primarily in leukocytes, has been the subject of substantial re-
search for its role in inﬂammatory diseases. However, the role of
PI3Kg inhibition in suppressing autoimmune T1D remains to be
explored. We tested the role of the PI3Kg inhibitor AS605240 in
preventing and reversing diabetes in NOD mice and assessed the
mechanisms by which this inhibition abrogates T1D. Our data in-
dicate that the PI3Kg pathway is highly activated in T1D. In NOD
mice, we found upregulated expression of phosphorylated Akt
(PAkt) in splenocytes. Notably, T regulatory cells (Tregs) showed
signiﬁcantly lower expression of PAkt compared with effector
T cells. Inhibition of the PI3Kg pathway by AS605240 efﬁciently
suppressed effector T cells and induced Treg expansion through
the cAMP response element-binding pathway. AS605240 effectively
prevented and reversed autoimmune diabetes in NOD mice and
suppressed T-cell activation and the production of inﬂammatory
cytokines by autoreactive T cells in vitro and in vivo. These studies
demonstrate the key role of the PI3Kg pathway in determining the
balance of Tregs and autoreactive cells regulating autoimmune
diabetes. Diabetes 61:1509–1518, 2012
P
hosphoinositide 3-kinases (PI3Ks) are a family
of dual-speciﬁcity kinases with roles in multi-
ple intracellular signaling pathways (1). The
phosphoinositides, which are phosphorylated by
PI3Ks at the 39-OH position of the inositol ring, work as
a docking platform for lipid-binding domains of various
cellular proteins, such as protein kinase-B (PKB)/Akt. The
latter triggers downstream kinase cascades involved in
many cellular functions including cell survival and pro-
liferation (2). Although PI3Ks are grouped into three classes,
class I is the most studied and the most clinically relevant
(1). Class IA includes three catalytic subunits, p110a,p 1 1 0 b,
and p110d, that are activated through tyrosine-kinase sig-
naling (3). Class IB (PI3Kg) is mainly activated by seven
transmembrane G-protein-coupled receptors, which include
the chemokine receptors (1,4). PI3Kg has been shown to
regulate T-cell activation in a T-cell receptor-dependent
manner (5–7). Whereas expression of the PI3Ka and
b-subunits is ubiquitous, PI3Kg expression is mainly re-
stricted to the hematopoietic system (8), which may limit
the toxicity of speciﬁc inhibition compared with pan-PI3K
inhibition. This has sparked great interest in its role in in-
ﬂammatory diseases such as chronic obstructive pulmonary
disease, pancreatitis, rheumatoid arthritis, and systemic lupus
erythematosus (SLE) (8–10). As of yet, no data are available
on the role of the PI3Kg pathway in modulating autoimmune
responses in type 1 diabetes (T1D) (11–13). Inhibiting a key
signaling enzyme in the activation of T cells such as the
PI3Kg molecule can constitute a novel therapeutic mo-
dality for T1D, an autoimmune disease characterized by
selective damage to pancreatic b-cells mediated mainly by
autoreactive T cells (CD4
+ and CD8
+)( 1 4 , 1 5 ) .I nt h i ss t u d y ,
we used AS605240, a PI3Kg inhibitor (PI3Kg-i) (Merck-
Serono), which has shown promising results in several animal
disease models (8,9,16,17). We tested the effect of this
PI3Kg-i in preventing and reversing T1D in NOD mice in
order to provide mechanistic data. Our results highlight
the role of the PI3Kg pathway in determining the balance
of T regulatory cells (Tregs) and autoreactive cells in the
pathogenesis of T1D.
RESEARCH DESIGN AND METHODS
Mice. Female NOD/ShiLtJ, BDC2.5, NOD-scid, and C57BL/6 mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME). Animals were main-
tained under speciﬁc pathogen-free conditions at Harvard Medical School.
Acquisition of PI3Kg-i. AS605240 was obtained through collaboration with
Thomas Ruckle at Merck-Serono. Details of the compounds were reported
previously (8,9).
Flow cytometric analysis. Anti-mouse Abs for CD62L, CD44, CD4, CD25, CD8,
CD11c, CD11b, B220, Annexin (phycoerythrin), 7AAD (PerCP; BD Biosciences),
forkhead box protein 3 (FoxP3; eBioscience), and PAkt (S473) (Cell Signaling
Technology) were used for ﬂuorescence-activated cell sorter (FACS) analysis.
Autoreactive T-cell proliferation assay. A total of 5 3 10
5 BDC2.5 splenocytes
and 50 mg/mL BDC2.5-peptide were incubated in vitro in a 96-well round-bottom
plate for 48 h. We then pulsed the cultures with 1 mCi of tritiated thymidine [
3H]
to determine cell proliferation.
Enzyme-linked immunospot assay measuring autoreactive T-cell activity.
A total of 5 3 10
4 irradiated NOD dendritic cells, 1 3 10
5 CD4
+ BDC2.5 T cells,
and 100 ng/mL BDC2.5-islet-peptide for in vitro studies and 1 3 10
6 splenocytes
with 100 mg/mL BDC2.5-islet-peptide for ex vivo prevention studies were used
to assess IFN-g as described previously (18). We subtracted the number of spots
counted in the negative control (absence of peptide) from the number of spots
in the stimulated cultures.
Akt (Thr
308) ELISA assay. ELISA assay was performed according to man-
ufacturer’s protocol [PhosphoDetect Akt (Thr
308); Calbiochem, San Diego, CA].
Luminex assay. A 21-plex cytokine kit (Millipore, St. Charles, MO) and an
8-plex-Multi-Pathway Signaling Kit-Phosphoprotein (Milliplex MAP Kit; Millipore)
were used according to the manufacturer’s instructions.
Pancreas pathology and immunohistochemistry. Pancreas immunohistol-
ogy was performed as described by our group previously (19). For the quan-
tiﬁcation of the PAkt
+CD3
+ cells, ﬁve high-power ﬁeld areas of spleen were
enumerated for color. Green color represented PAkt
+ cells; red color represented
CD3
+ cells. The number of cells showing double positivity for PAkt
+ and CD3
+
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+PAkt
+ cells
to positive CD3
+ was calculated. The mean of the percentage of the ﬁve areas
was calculated.
Insulitis score. Insulitis scoring was performed on hematoxylin and eosin–
stained pancreatic sections. A score of 0–4 was assigned based on islet in-
ﬁltration by a blinded pathologist, as previously described (20). Insulitis scores
were graded as follows: grade 0, normal islets; grade 1, mild mononuclear
inﬁltration (,25%) at the periphery; grade 2, 25–50% inﬁltration; grade 3, .50%
inﬁltration; and grade 4, islets completely inﬁltrated with no residual paren-
chyma remaining. At least 30 islets per group were analyzed and pooled from
sections obtained from at least four different mice.
Isolation of cells from pancreas. The minced pancreas was washed twice
with 10 mL Hanks’ balanced salt solution plus 10% fetal calf serum. The tissue
was resuspended with 10 mL of Iscove’s modiﬁed Dulbecco’s medium con-
taining 1 mg/mL collagenase (type IV; Sigma Chemical, St. Louis, MO) and
incubated in a water bath for 30 min at 37°C with continuous shaking (100
cycles/min). Lymphocytes were isolated by Percoll technique and assessed
with FACS analysis.
CD4
+ T-cell extraction and CD25
+ T-cell depletion. CD4
+ cell extraction
and CD25
+ cell depletion from splenocytes of NOD or BDC2.5 mice were
conducted using magnetic microbeads (Miltenyi Biotec, Auburn, CA). As
measured by FACS analysis, the isolated cell population had a purity .95%.
Treg generation assay. A total of 2.5 3 10
5 CD4
+ T cells from NOD mice were
cultured for 72 h with 1 mg/mL anti-CD3, 1 mg/mL anti-CD28, and 1 ng/mL
transforming growth factor-b (TGF-b) with and without AS605240 (5 mM).
Adoptive cell transfer. A total of 20 3 10
6 whole splenocytes or Treg-
depleted splenocytes extracted from hyperglycemic NOD mice or AS605240-
treated mice were adoptively transferred into NOD-scid hosts. Onset of
diabetes was monitored at least three times per week.
Western blot. Western blots were performed as previously described (21).
Statistical analyses. Data are expressed as mean 6 standard error. Kaplan-
Meier analysis was used for survival analysis, and a log-rank comparison of the
groups was used to calculate P values. The t test was used for comparison of
means between the experimental groups. Differences were considered to be
signiﬁcant when P was ,0.05.
RESULTS
PI3Kg-i AS605240 suppresses intracellular PAkt in
splenocytes of NOD mice. To examine the activity of the
PI3K–Akt pathway in autoimmune diabetes, lysates of
splenocytes from early diabetic NOD mice were subjected
to an ELISA assay that measures the level of Akt protein
phosphorylated at Thr
308. As shown in Fig. 1A,P A k te x -
pression was signiﬁcantly increased in the splenocytes of
NOD mice compared with those from naive C57BL/6 mice
of the same age. We then assessed the expression of PAkt in
spleens of untreated NOD mice versus NOD mice treated
with 30 mg/kg of AS605240 administered i.p. daily for 7
days. Immunohistochemistry of splenocytes using 4’,6-
diamidino-2-phenylindole, CD3, and intracellular PAkt staining
was performed. Histological analysis revealed signiﬁcant
suppression of positive PAkt in splenocytes of treated mice
compared with control mice. The percentage of CD3
+ cells
expressing PAkt was signiﬁcantly reduced in treated com-
pared with control mice (38.04 6 11.03% vs. 65.40 6 6.78%,
respectively; P = 0.002) (Supplementary Fig. 1). Western
blot performed on splenocytes from AS605240-treated and
control NOD mice showed suppression of PAkt in the spleen
of treated NOD mice compared with control (Fig. 1B).
FIG. 1. AS605240 suppresses intracellular PAkt in splenocytes of NOD mice and delays diabetes onset. A: PAkt measurement by an ELISA assay of
lysates from splenocytes of 12-week-old C57BL/6 and NOD mice shows higher levels of PAkt in NOD mice (*P < 0.05; n = 4 mice in each group).
B: Western blot analysis of lysates from splenocytes of NOD mice treated with either AS605240 (30 mg/kg) or PBS control for 7 days (n = 3 mice in
each group). C: Kaplan-Meier cumulative survival of NOD mice treated with AS605240 starting at 10 weeks of age showed 100% prevention for the
duration of treatment of 7 weeks. The difference remains signiﬁcant up to 15 weeks postinitial treatment (P < 0.05; n =1 2 –15 mice in each group).
D: Representative example of IFN-g ELISpot analysis after an ex vivo BDC2.5 pancreatic-peptide challenge of splenocytes isolated from nor-
moglycemic NOD mice treated for 3 weeks compared with age-matched control NOD mice. Bar graph represents the frequency of IFN-g–producing
autoreactive cells (*P < 0.05; n = 4 mice in each group). Results are presented as the mean 6 SEM. (A high-quality color representation of this
ﬁgure is available in the online issue.)
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betic NOD mice. Ten-week-old prediabetic NOD mice were
injected with 30 mg/kg of AS605240 i.p. daily for 7 weeks. As
s h o w ni nF i g .1 C, AS605240 conferred 100% protection
during the course of 7 weeks of therapy. Following discon-
tinuation of therapy, 50 and 25% of the NOD mice remained
free from diabetes at 25 and 30 weeks of age, respectively.
No survival difference was observed in the NOD mice
treated with the same volume of PBS (vehicle for the
AS605240) as compared with untreated control (P =0 . 7 ;
n = 6 in each group). Histopathological analysis of the
pancreatic islet morphology and inﬁltration was also per-
formed at 3 and 10 weeks postinitial treatment on control
and treated animals (n = 4 mice/group). The AS605240-
treated NOD mice had well-preserved islets with strong
insulin staining at 3 weeks postinitial treatment and a sig-
niﬁcantly lower insulitis score, whereas substantial islet
inﬁltration was observed in untreated mice (Supplementary
Fig. 2). We assessed the activity of autoreactive CD4
+
T cells by measuring cytokine patterns after a BDC2.5-
pancreatic-peptide challenge of splenocytes recovered from
AS605240-treated and untreated NOD mice at 3 and 10
weeks postinitial treatment as previously described (19).
Treated mice had a signiﬁcantly lower frequency of auto-
reactive IFN-g–producing CD4
+ cells compared with un-
treated NOD mice after 3 weeks of treatment (P =0 . 0 2 )
(Fig. 1D). At 20 weeks of age, AS605240-treated NOD
mice showed minimal inﬁltration compared with the
age-matched untreated control mice (Fig. 2A). Insulitis
scoring was performed, which showed a signiﬁcantly
lower grade of insulitis in the AS605240-treated mice
compared with the untreated NOD age-matched groups
(Fig. 2B).
AS605240 suppresses autoreactive T cells while in-
creasing Tregs in NOD mice. An enzyme-linked immuno-
spot (ELISpot) assay on recovered splenocytes stimulated
with BDC2.5-peptide ex vivo showed that treated animals
had signiﬁcantly lower frequency of autoreactive IFN-g–
producing CD4
+ cells compared with untreated NOD mice at
10 weeks postinitial treatment (P =0 . 0 2 )( F i g .2 C). Similarly,
Luminex was used on supernatant collected from the ELI-
Spot assay to measure various cytokines and chemokines
involved in the pathogenesis of T1D. Our data showed
marked suppression of inﬂammatory cytokines including
Th1, Th2, and Th17 cells as well as IFN-g–inducible pro-
tein-10, monocyte chemoattractant protein-1, and regu-
lated on activation, normal T cell expressed and secreted
chemokine secretion at 20 weeks of age (Fig. 2D). Flow
cytometric analysis of splenocytes showed a decrease
in the absolute number of effector CD4
+ and CD8
+ T cells
identiﬁed as CD44
highCD62L
low at 10 weeks post-initial
treatment (Fig. 2E), which was concurrent with a signiﬁcant
increase in the percentage of regulatory CD4
+CD25
+FoxP3
+
cells in spleens of treated versus untreated mice (16.55 6
1.6% vs. 9.84 6 1.3%, respectively; P = 0.02) (Fig. 2F and G),
with a tendency toward statistical signiﬁcance in the ab-
solute number (1.62 6 0.19 3 10
6 vs. 1.28 6 0.05 3 10
6,
respectively; P =0 . 0 7 )( F i g .2 E). Of note, no difference
was observed in the percentage of plasmacytoid dendritic
cells deﬁned as CD11c
+CD11b
2B220
+ in the spleens of
treated mice compared withc o n t r o lm i c ea t2 0w e e k so f
age (0.76 6 0.09% vs. 0.73 6 0.09%; P =0 . 4 ) .
AS605240 suppresses autoreactive T cells in vitro.
Stimulating CD4
+ BDC2.5 T cells with BDC2.5-peptide in
vitro in the presence of AS605240 showed a dose-dependent
suppression of autoreactive CD4
+ T-cell proliferation in
vitro (Fig. 3A) and production of IFN-g in an ELISpot assay
(Fig. 3B). We also examined the effect of PI3Kg inhibition
on the production of cytokines and chemokines pertinent
to the pathogenesis of T1D by subjecting supernatant from
the ELISpot to a Luminex assay (22). Autoreactive T cells
treated with AS605240 also produced fewer multiple in-
ﬂammatory cytokines such as IL-6 and IL-17 and chemo-
kines such as IFN-g–inducible protein-10 and monocyte
chemoattractant protein-1 as shown in Fig. 3C. Adding
IFN-g (4 ng/mL), IL-2 (2 ng/mL), IL-6 (2 ng/mL), IL-17
(10 ng/mL), or a combination of these cytokines to the
autoreactive assay failed to restore proliferation of the
CD4
+ BDC2.5 T cells inhibited by AS605240 (data not
shown). Furthermore, we investigated whether AS605240
caused an increased rate of T-cell death, which in turn
could provide an explanation for the lack of activation. No
increase in cell death (positive for 7AAD and Annexin) or
apoptosis (positive for Annexin and negative for 7AAD) was
observed in CD4
+ T cells treated with AS605240 (Supple-
mentary Fig. 3).
AS605240 results in the expansion of Tregs. We then
assessed the effects of inhibiting the CD4
+ Tc e l lP I 3 K g
p a t h w a yo nT r e gg e n e r a t i o ni nv i t r o .At o t a lo f2 . 53 10
5 CD4
+
T cells from NOD mice were cultured for 72 h in a Treg-
generation assay, as described previously, using anti-CD3/
CD28 stimulation and TGF-b with and without AS605240
(23,24). Flow cytometric analysis for CD4
+CD25
+FoxP3
+
revealed a signiﬁcant increase of FoxP3
+ cells treated with
AS605240 compared with untreated cells stimulated with
anti-CD3/CD28 and TGF-b as measured by percentage
(Fig. 3D) and absolute number (12 6 1.72 3 10
3 vs. 6.1 6
1.5 3 10
3, respectively; P = 0.02). However, no difference
in Tregs was observed when the PI3Kg-i was added to CD4
+
T cells stimulated with anti-CD3/CD28 in the absence of
TGF-b, as measured by percentage (Fig. 3D) and absolute
number (2.97 6 0.54 3 10
3 vs. 3.46 6 0.64 3 10
3,r e -
spectively; P = 0.2). No signiﬁcant increase in FoxP3
+ cells
was observed when CD25
+-depleted CD4
+ T cells were
treated with AS605240 compared with control (anti-CD3/
CD28 and TGF-b) (data not shown). For the in vivo analysis,
10 3 10
6 BDC2.5 splenocytes with and without CD25
+ de-
pletion were injected into the tail vein of NOD-scid mice.
Both conditions were either treated by daily i.p. injections of
30 mg/kg AS605240 or left untreated. Results showed a sig-
niﬁcantly increased CD4
+CD25
+FoxP3
+ Treg population in
the spleen 7 days posttransfer of BDC2.5 splenocytes in the
treated group compared with control by percentage analysis
(22.73 6 3.47% vs. 12.54 6 0.60%, respectively; P = 0.02) and
absolute count (3.80 6 1.47 3 10
5 vs. 0.83 6 0.29 3 10
5,
respectively; P = 0.05). However, no signiﬁcant increase in
the CD4
+CD25
+FoxP3
+ Treg population was observed af-
ter injection of CD25
+-depleted splenocytes whether they
were followed by treatment or not (Fig. 3E).
cAMP response element-binding signaling is responsi-
ble for the expansion of Tregs under PI3Kg inhibition.
We then examined cell lysates from CD4
+ T cells retrieved
from the in vitro Treg-generation assay described above
using anti-CD3/CD28 and TGF-b with or without PI3Kg-i
by an 8-plex Multi-Pathway Signaling Kit-Phosphoprotein
(Milliplex MAP Kit; Millipore). We found that the addition
of PI3Kg-i increased the expression of phosphorylated
cAMP response element-binding (CREB) compared with
control (anti-CD3/CD28 and TGF-b). No differential
increase was noted in the expression of extracellular
signal–related kinase/mitogen-activated protein kinase,
signal transducer and activator of transcription (STAT) 3,
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P70 S6 kinase, and p38 (Fig. 4A). CREB, a nuclear transcrip-
tion factor responsible for cell survival and proliferation,
was recently shown to increase FoxP3 transcription by
binding to its promoter (25). We then examined the effect of
CREB inhibitor on Tregs generation in our assay (26). Ad-
dition of PI3Kg-i–expanded Tregs signiﬁcantly compared
with control (anti-CD3/CD28 and TGF-b)( 3 0 . 4 06 2% vs.
14.65 6 2.4%, respectively; P = 0.04). However, the addition
of CREB inhibitor at 40 mmol/L to anti-CD3/CD28, TGF-b,
and PI3Kg-i suppressed Treg generation compared with anti-
CD3/CD28, TGF-b,a n dP I 3 K g-i (5.05 6 0.7% vs. 30.40 6 2%,
respectively; P = 0.04, Fig. 4B and C). Furthermore, addition
of the same concentration of CREB inhibitor to anti-CD3/
CD28 and TGF-b h a dn os i g n i ﬁcant effect on Treg generation
compared with control (18.43 6 3.3% vs. 14.65 6 2.4%, re-
spectively; P =0 . 5 ;F i g .4 B and C). No increase in cell death
(positive for 7AAD and Annexin) or apoptosis (positive for
Annexin and negative for 7AAD) was observed in CD4
+
T cells treated with CREB inhibitor (data not shown).
AS605240 treatment reverses hyperglycemia in newly
hyperglycemic NOD mice. For reversal studies, NOD
mice were observed for the development of hyperglyce-
mia (.250 mg/dL). After two consecutive hyperglycemic
FIG. 2. Prediabetic NOD mice were treated with AS605240 for 7 weeks beginning at 10 weeks of age. A: Representative example of pancreatic
histology from AS605240-treated group and untreated control at 20 weeks of age. Insulitis score at 20 weeks of age measured on 30 different
islets from four mice per group is presented in B.I F N - g ELISpot analysis (C) and Luminex assay on supernatant (D)f r o ma ne xv i v oB D C 2 . 5 -
pancreatic-peptide challenge of splenocytes recovered from AS605240-treated mice compared with control NOD mice at 20 weeks of age (*P <
0.05, n = 4 mice in each group). E: Flow cytometry analysis on splenocytes from treated mice at 20 weeks of age shows signiﬁcant suppression of
the absolute count of CD4 effector T cells (CD4
+CD44
highCD62L
low) and CD8 effector T cells (CD8
+CD44
highCD62L
low) while sparing Tregs
(CD4
+CD25
+FoxP3
+) compared with control (*P < 0.05; n = 4 mice in each group). F: Representative example of FACS staining from splenocytes
of treated and control NOD mice at 20 weeks of age shows higher percentage of Tregs (CD4
+CD25
+FoxP3
+) in treated compared with control
mice. G: Bar graph shows the percentage of Tregs analyzed by ﬂow cytometry in splenocytes of treated mice compared with control at 20 weeks
of age (*P < 0.05; n = 4 mice in each group). Results are presented as the mean 6 SEM. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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given 30 mg/kg of AS605240 i.p. daily for 3 weeks. None of
the hyperglycemic NOD mice treated i.p. with PBS showed
reversal of hyperglycemia (Fig. 5A). We observed diabetes
reversal in 73% of AS605240-treated NOD hyperglycemic
mice by the end of the 3 weeks of treatment (11 out of 15
treated hyperglycemic NOD mice). Twenty-ﬁve percent of
mice showed long-standing reversal of diabetes following
the discontinuation of AS605240 (Fig. 5B). Notably, an
e x t e n d e d8 - w e e kt r e a t m e n tr e g i m e nr e s u l t e di na ni n i t i a l
reversal rate of 80% in the diabetic mice (four out of ﬁve
mice) and normoglycemia for at least 13 weeks post-initial
treatment in the reversed-treated mice. Three out of the four
mice were still normoglycemic .10 weeks after stopping
administration of AS605240 (Fig. 5C). Histological analysis
of untreated NOD mice after 3 weeks postonset of hyper-
glycemia showed necrotic islets with negative-staining in-
sulin. In contrast, treated mice showed a lower percentage
of inﬁltrates conﬁned to the border of islets, positive FoxP3
cells, and strong staining for insulin (Supplementary Fig. 4).
AS605240 treatment reverses hyperglycemia in early
diabetic NOD mice through Tregs. Reversal NOD mice
at 100 days postreversal had a signiﬁcant increase in pe-
ripheral Tregs compared with age-matched diabetic NOD
mice (Fig. 5D). To ensure the functionality of Tregs, 20 3
10
6 splenocytes (with and without CD25 depletion) from
normoglycemic reversed NOD mice treated with AS605240
or untreated hyperglycemic NOD mice were adoptively
transferred into NOD-scid mice. The control groups re-
ceiving whole splenocytes and CD25-depleted splenocytes
from early diabetic NOD mice developed diabetes at 3 to 4
weeks of age. Likewise, mice receiving cells from non-
diabetic 12-week-old NOD mice developed diabetes 3–5
weeks later. In comparison, mice injected with undepleted
splenocytes obtained from reversed-treated NOD mice
developed diabetes after 6–8 weeks, thus delaying diabetes
onset by an additional 3–5 weeks when compared with
mice receiving adoptive transfer of splenocytes from di-
abetic NOD mice. Depletion of CD25
+ cells in the spleno-
cytes of reversed mice abrogated the delay in diabetes
FIG. 3. AS605240 suppressed in a dose-dependent manner the proliferation of BDC2.5 CD4
+ T cells stimulated by the BDC2.5-pancreatic-peptide in
vitro as measured by thymidine incorporation (A) and their production of IFN-g in an ELISpot assay (B)( * P < 0.05, n =3 –5 mice; data are
representative of three separate experiments). The negative control (ctrl) splenocytes received no peptide stimulation, whereas the positive
control cells were stimulated with the BDC2.5-peptide. C: Luminex assay was used on supernatant collected from the ELISpot assay. AS605240
potently suppressed inﬂammatory cytokines and chemokines produced by BDC2.5 CD4
+ T cells stimulated by the BDC2.5-pancreatic-peptide in
vitro (*P < 0.05; n =3 –5 mice; data are representative of two separate experiments). D: Representative example of FACS staining shows the effect
of the AS605240 on Treg generation in vitro using a CD3/CD28 stimulation assay with and without TGF-b. Cells are gated on CD4
+ T cells. Data
represent one of three separate experiments. The bar graph represents the percentage of Tregs from these experiments (*P < 0.05; n =3 –5 mice;
data are representative of three separate experiments). E: Bar graph shows the absolute counts of Tregs in the spleen of NOD-scid mice that
received an adoptive transfer of either whole BDC2.5 splenocytes or CD25
+ depleted BDC2.5 splenocytes, followed by treatment with AS605240
for 7 days, as compared with untreated control receiving an adoptive transfer (*P < 0.05; n = 4 mice in each group). Results are presented as the
mean 6 SEM. (A high-quality color representation of this ﬁgure is available in the online issue.)
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+ depleted
splenocytes from reversed NOD mice led to the development
of diabetes within 3 weeks postinjection.
AS605240 treatment suppresses T-cell inﬁltration in
pancreatic islets while increasing Tregs. FACS analysis
of lymphocytes isolated from pancreata of reversed mice 3
weeks after daily treatment with PI3Kg-i shows signiﬁ-
cant suppression of CD4
+ and CD8
+ Tc e l l si n ﬁltrating the
pancreas in treated compared with PBS-treated mice
(Fig. 6A and B). The percentage of CD4
+ T cells in treated
mice expressing FoxP3 as a marker of Tregs were signiﬁ-
cantly higher compared with PBS-treated mice (57.88 6
7.84% vs. 17.87 6 5.60%, respectively; P = 0.006) (Fig. 6C).
No difference was observed in the Treg absolute count
between treated and control mice (21.12 6 6.29 3 10
3 vs.
18.36 6 6.00 3 10
3, respectively; P = 0.7). Of note, no dif-
ference was observed in the absolute number of dendritic
cells in the pancreas between treated and PBS-treated mice
(15330 6 37 vs. 16150 6 54, respectively; P =0 . 9 1 ) .N o
difference was observed in the pancreatic lymph nodes
(89.75 6 26.54 3 10
3 vs. 67.24 6 10.54 3 10
3, respectively;
P =0 . 4 6 )
PI3Kg inhibition suppresses the expression of PAkt
(Ser473) in splenocytes of reversed mice. Spleens from
PI3Kg-i–treated and PBS-treated NOD mice were subjected
to phospho-FACS analysis. AS605240 treatment signiﬁ-
cantly reduced CD4
+ and CD8
+ T cells expressing high
levels of PAkt (Ser
473) in reversed NOD mice 3 weeks
posttreatment (Fig. 6D and E). Tregs from spleens of treated
or control mice, deﬁned as CD4
+CD25
+FoxP3
+, expressed
lower levels of intracellular PAkt (Ser
473) compared with
effector cells, deﬁned as CD4
+CD25
+FoxP3
2 (Fig. 6F).
Establishing PI3Kg inhibition-based strategies to
reverse T1D. Given the overt toxicity and lack of efﬁ-
cacy of monotherapeutic strategies, the need for developing
combinatorial strategies is more pressing than ever before
(27). We tested the combination of PI3Kg inhibition with
one of the most clinically relevant immunomodulatory
agents, anti-CD3 (28). We treated our hyperglycemic mice
(deﬁned as above) with a combination of AS605240 and
anti-CD3 with one group receiving a single dose of anti-CD3
(12.5 mg) i.p. at the onset of hyperglycemia and the other
receiving additional daily injections of AS605240 (30 mg/kg)
i.p. daily for 3 weeks. As shown in Fig. 7A, none of the hy-
perglycemic anti-CD3–treated NOD mice showed reversal of
hyperglycemia. However, our combinatorial protocol re-
sulted in hyperglycemia reversal in 67% of the treated NOD
mice (four out of six mice). All of the treated mice main-
tained normoglycemia for at least 13 weeks following the
initiation of treatment (Fig. 7B). Finally, as mammalian
FIG. 4. A: Cell lysate analysis by Luminex assay of CD4
+ T-cells retrieved from the in vitro Treg-generation assay (anti-CD3/CD28 stimulation and
TGF-b) at 20 min showed an increase in the phosphorylation of the nuclear transcription factor CREB under PI3Kg pathway inhibition compared
with untreated control (data represent one of three separate experiments). B: Representative example of FACS staining showing the effect of the
CREB inhibition on Treg generation in vitro using a CD3/CD28 stimulation assay with TGF-b with or without PI3Kg-i (data represent one out of
three separate experiments). The percentages of Tregs from these different conditions are shown in the bar graph in C (*P < 0.05; n =3 –5 mice;
data are representative of three separate experiments). Results are presented as the mean 6 SEM. (A high-quality color representation of this
ﬁgure is available in the online issue.)
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pathway, we were interested in comparing the therapeutic
efﬁcacy of rapamycin to that of AS605240 in early diabetic
NOD mice. Hyperglycemic NOD mice were given 1 mg of
rapamycin i.p. at days 0, 2, 4, 6, 8, and 10. As shown in Fig.
7C, none of the hyperglycemic NOD mice treated with
rapamycin showed reversal of hyperglycemia.
DISCUSSION
There has been a signiﬁcant increase in the incidence of
T1D worldwide, rendering the disease a major global
health care problem with no currently available cura-
tive therapy (12). Although clinical trials using known
immunosuppressants have yielded promising results in
preventing T1D, they have not met expectations due to
their inadequacy and serious morbidity (13,29). This has
prompted investigators to search for alternatives. In this
regard, the PI3K pathway is an attractive target for T1D
therapy. Among the various classes of PI3Ks, PI3Kg is
expressed mainly in leukocytes (8). The role of PI3Kg in
thymocyte survival and activation of mature T cells was ﬁrst
highlighted in mice lacking the p110 catalytic subunit of
PI3Kg (7,30,31). Barber et al. (32) has shown that deletion
of the PI3K–PKB pathway, downstream of PI3Kg, decreases
survival of pathogenic CD4
+ memory cells in mouse models
of SLE. PI3Kg has also been shown to play a critical role in
the downstream signaling of TCR-mediated T-cell activation
(5). The PI3Kg pathway has also been shown to play
a critical role in the chemotaxis of leukocytes as well (8,33).
Although a growing body of work has highlighted the role of
anti-PI3Kg strategies in various diseases, the role of such
therapy in T1D is unknown (8,9,16,34–36).
In this report, we have examined the immunoregulatory
function of AS605240 in regulating T1D. We observed a
signiﬁcant activation of the PI3K–PKB pathway in the
splenocytes of diabetic NOD mice compared with the
splenocytes of C57BL/6 mice. AS605240 prevented T1D in
FIG. 5. A: Blood glucose of PBS-treated early diabetic NOD mice shows absence of reversal in 100% of the mice (n = 7 mice). B: Blood glucose of
treated early diabetic NOD mice with 30 mg/kg of AS605240 shows a 73% rate of reversal at 3 weeks post-start of treatment that becomes 25% at
13 weeks post-start of treatment (n = 14 mice). C: Blood glucose of treated early diabetic NOD mice with 30 mg/kg of AS605240 for 8 weeks shows
80% reversal at 10 weeks post-start of treatment (n = 5 mice). D: Representative example of FACS staining from splenocytes of treated reversal
mice and age-matched diabetic NOD mice. Bar graph shows the absolute count of Tregs analyzed by ﬂow cytometry in splenocytes of treated
reversal mice compared with age-matched diabetic NOD mice (*P < 0.05; n = 4 mice in each group). E: Kaplan-Meier cumulative survival curves of
diabetes onset in NOD-scid mice that received splenocytes harvested from treated reversal mice with or without CD25 depletion or from early
diabetic control mice with or without CD25 depletion. Depleting Tregs prior to transfer of splenocytes into NOD-scid mice abrogates the delay in
inducing diabetes by the splenocytes of reversal mice. No difference in diabetes onset was observed in NOD-scid mice that received splenocytes
from early diabetic control mice with or without CD25 depletion (n = 3 to 4 mice in each group). Results are presented as the mean 6 SEM. (A high-
quality color representation of this ﬁgure is available in the online issue.)
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Although PI3Kg inhibition potently abrogated autoreactive
T cells, it spared Tregs. Importantly, AS605240 increased
the ratio of Tregs to effector populations in the treated
mice, tipping the balance from autoreactive T cells to Tregs,
thus conferring protection against autoimmune diabetes.
This ratio has been reported to be central to the suppres-
sion of autoreactive T cells (37). Ablation of Tregs in the
BDC2.5/NOD mouse model of autoimmune diabetes leads
to accelerated disease development (38). PI3Kg inhibition
suppressed autoreactive T cells along with chemokines and
inﬂammatory cytokines shown to play a role in the patho-
genesis of T1D in vitro and in vivo (22,39–41). Moreover, we
showed that PI3Kg inhibition results in increased Tregs
in vitro and in vivo. We then studied signaling pathways
known to induce FoxP3 expression, including extracel-
lular signal–related kinase/mitogen-activated protein kinase,
STAT3, P70 S6 kinase, inhibitory NF-kBa, CREB, Jun NH2-
terminal kinase, STAT5A/B, and p38 (25,42–48). Phosphor-
ylated CREB was elevated in CD4
+ T cells treated with
PI3Kg-i in our Treg generation assay. This increase was
associated with higher Treg generation, whereas the in-
hibition of CREB was associated with Treg suppression.
This suggests that PI3Kg inhibition may act on Treg gen-
eration through the CREB pathway. The more pronounced
suppression of Tregs generation observed in the PI3Kg-i
group compared with control could be related to the in-
teraction of PI3K and CREB on T-cell activation and the
synergistic suppressive effect of their inhibitors on T-cell
function. Although the role of Akt in the expression of
FoxP3 is described, the downstream mechanisms involved
in FoxP3 transcription are not well known (49). Our data
provide new insights on the interplay between the PI3Kg
pathway and the CREB pathway in the induction of FoxP3
transcription and its application in T1D.
Achieving effective and durable reversal of T1D has been
very challenging, and ﬁnding a cure is extremely desirable.
AS605240 reversed T1D in ;80% of early diabetic NOD
mice. In accordance with our in vitro data, Tregs were
found to be increased in the spleen of treated reversal
NOD mice compared with control NOD mice of the same
age. Moreover, the pancreas of treated reversal NOD
mice showed signiﬁcant suppression of CD4
+ and CD8
+
T cells compared with PBS-treated mice. Interestingly, the
remaining CD4
+ T cells in treated mice mostly expressed
FoxP3, a marker of Tregs, compared with PBS-treated
mice. Our data indicate that expression of PAkt was pref-
erentially higher in effector T cells. Notably, CD4
+ effector
T cells had signiﬁcantly higher levels of PAkt compared
with Tregs in treated and control mice. Treated reversal
mice also showed signiﬁcant reduction in CD4
+ and CD8
+
T cells expressing high levels of PAkt (Ser
473) compared
with PBS-treated controls. Our data suggest that the level
of PAkt in an individual cell will determine its function as
an effector or regulatory cell and that inhibition of PAkt
will tip the balance from effector to regulatory cell.
FIG. 6. A: Representative example of FACS staining of cells isolated from pancreas of NOD mice treated with either AS605240 or PBS vehicle for 3
weeks. Dot plots show gating on CD4
+ and CD8
+ T cells. B: The bar graph represents the absolute number of CD4
+ and CD8
+ T cells in the PI3Kg-i–
treated mice compared with control (*P < 0.05; n = 3 to 4 mice in each group). C: Representative example of FACS staining of cells isolated from
pancreas of NOD mice treated with either AS605240 or PBS vehicle. Cells are gated on CD4
+ T cells and show FoxP3 expression. Bar graph
represents the percentage of Tregs in cells isolated from pancreas of PI3Kg-i–treated mice compared with control PBS-treated NOD mice (*P <
0.05; n = 3 to 4 mice in each group). D: Bar graph represents the percentage of CD4
+ T cells highly expressing PAkt by ﬂow cytometry in spleens of
PI3Kg-i–treated mice compared with control PBS-treated mice (*P < 0.05; n = 3 to 4 mice in each group). E: Bar graph represents the percentage of
CD8
+ T cells highly expressing PAkt (*P < 0.05; n = 3 to 4 mice in each group). F: Representative example of FACS staining of PAkt expression in
CD4
+CD25
+FoxP3
+ Tregs compared with CD4
+CD25
+FoxP3
2 non-Tregs in splenocytes of treated NOD mice. Bar graph shows the mean ﬂuores-
cence intensity (MFI) of PAkt expression in CD4
+CD25
+FoxP3
+ Tregs compared with CD4
+CD25
+FoxP3
2 non-Tregs in splenocytes of NOD mice
treated with either AS605240 or PBS vehicle (control) (*P < 0.05; n = 3 to 4 mice in each group). Results are presented as the mean 6 SEM.
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to self-antigens in our system, at 100 days, we adoptively
transferred splenocytes with and without Tregs from the
treated reversed mice into NOD-scid mice. As compared with
the splenocytes from early diabetic NOD mice, splenocytes
from reversal-treated mice induced hyperglycemia later
in NOD-scid mice. Depleting Tregs in splenocytes of the
reversal mice abrogated this delay.
Major efforts are now underway to explore various
options to further improve the outcome of combinational
therapies (27). Anti-CD3 was reported to reverse diabetes
in 75–80% of early diabetic NOD mice (50,51). Furthermore,
anti-CD3 administered to patients with new-onset T1D
preserved residual b-cell function for at least 18 months.
However, the majority of patients treated with anti-CD3 had
signiﬁcant adverse events (52). A combination of a short-
duration PI3Kg inhibition therapy and low-dose anti-CD3
could overcome those limitations and constitute a novel
promising therapeutic strategy. To address the potential
role of mTOR blockade in reversing T1D, we show that
rapamycin does not reverse T1D, a result in concordance
with previous reports (53). Interestingly, Valle et al. (51)
have shown that rapamycin has a deleterious effect on T1D
by breaking the anti-CD3–induced tolerance in NOD mice.
These data indicate that blockade of mTOR does not play
the major role in the antidiabetic effect of PI3Kg inhibition
observed in this study.
It should be noted that future efforts are underway to
develop inhibitors with greater speciﬁcity to the PI3Kg
subunit. Although AS605240 has been demonstrated to be
speciﬁc to the PI3Kg subunit, we cannot rule out minimal
interaction with other subunits. Finally, whether the higher
level of PAkt in NOD splenocytes relative to C57BL/6
splenocytes is due to an inherent activation of the PI3K
pathway in NOD lymphocytes or due to the increased
frequency of pathogenic T cells remains an interesting
question for future studies.
In summary, these results provide vital preclinical data
to support the concept of translating PI3Kg inhibition ther-
apy to patients with T1D.
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FIG. 7. A: Blood glucose of early diabetic NOD mice treated with a single low-dose anti-CD3 (12.5 mg) shows no therapeutic effect in any of the
treated mice (n = 4 mice). B: Blood glucose of early diabetic NOD mice treated with a single low-dose anti-CD3 (12.5 mg) and 30 mg/kg of AS605240
for 3 weeks shows long-term reversal in ;70% of mice (n = 6 mice). C: Blood glucose of rapamycin-treated early diabetic NOD mice shows no
reversal of hyperglycemia (n = 5 mice).
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